SCHEMBL2877459

SCHEMBL2877459

CC1CN(C[C@@H]2CCc3cccnc3[C@@H](O)C2)CCC1c1ccccc1

nearest known ligand 0.79

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 19/20 0.79
KCNH2 Q12809 13/20 0.79
SIGMAR1 Q99720 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2877461 1.00 OPRL1 (0.79) OPRL1KCNH2SIGMAR1
SCHEMBL2883922 1.00 OPRL1 (0.79) OPRL1KCNH2SIGMAR1
SCHEMBL2877752 0.89 OPRL1 (1.00) OPRL1KCNH2
SCHEMBL2877749 0.89 OPRL1 (1.00) OPRL1KCNH2
SCHEMBL2882556 0.89 OPRL1 (1.00) OPRL1KCNH2
SCHEMBL2880928 0.87 OPRL1 (0.77) OPRL1KCNH2SIGMAR1
SCHEMBL2878375 0.87 OPRL1 (0.77) OPRL1KCNH2SIGMAR1
SCHEMBL2878377 0.87 OPRL1 (0.77) OPRL1KCNH2SIGMAR1
SCHEMBL6014222 0.83 OPRL1 (1.00) OPRL1KCNH2
SCHEMBL2884952 0.83 OPRL1 (1.00) OPRL1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 US claimed
EP-1726590-A1 CYCLOALKANOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP claimed
US-7855294-B2 Cycloalkanopyridine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-21 US disclosed
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 US disclosed
EP-1726590-A1 CYCLOALKANOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191419-A1 Cycloalkanopyridine derivative OPRL1, OPRK1, AVPR2 OPRL1 1/4885KCNH2 969/4885SIGMAR1 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.